EXACT Sciences Corp. (EXAS)

91.93
3.27 3.43
NASDAQ : Health Technology
Prev Close 95.20
Open 95.32
Day Low/High 90.01 / 96.13
52 Wk Low/High 37.36 / 97.27
Volume 2.45M
Avg Volume 1.83M
Exchange NASDAQ
Shares Outstanding 125.76M
Market Cap 11.92B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Exact Sciences Announces Offering Of $600 Million Convertible Senior Notes Due 2027

Exact Sciences Announces Offering Of $600 Million Convertible Senior Notes Due 2027

MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant...

Exact Sciences To Participate In March Investor Conferences

Exact Sciences To Participate In March Investor Conferences

MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp.

Cologuard Helps Screen Two Million People For Colorectal Cancer

Cologuard Helps Screen Two Million People For Colorectal Cancer

Exact Sciences Announces Milestone Ahead of Cologuard Classic, National Colorectal Cancer Awareness Month

Total 2018 Revenue Increased 71 Percent To $454 Million, And 934,000 People Were Screened With Cologuard

Total 2018 Revenue Increased 71 Percent To $454 Million, And 934,000 People Were Screened With Cologuard

- Fourth quarter revenue increased 64 percent to $143.0 million

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cronos, Fortinet, Dominion Energy and more.

Exact Sciences To Report $454-455M In Total Revenue, 71-percent Growth For 2018

Exact Sciences To Report $454-455M In Total Revenue, 71-percent Growth For 2018

- Cologuard test volume increased 64 percent, with approximately 934,000 tests completed in 2018

I Am Going to Quote You a Bunch of Statistics Tonight

Some are going to confirm the bearish bias.

Exact Sciences To Participate In J.P. Morgan Healthcare Conference

Exact Sciences To Participate In J.P. Morgan Healthcare Conference

MADISON, Wis., Dec.

Exact Sciences To Participate In Two November Investor Conferences

Exact Sciences To Participate In Two November Investor Conferences

MADISON, Wis., Nov.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Exact Sciences Stock: Buy at What Level?

Exact Sciences Stock: Buy at What Level?

Our strategy on EXAS shares after the company's latest earnings.

Costco, Tellurian, Exact Sciences: 'Mad Money' Lightning Round

Costco, Tellurian, Exact Sciences: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Costco, Tellurian, Exact Sciences, XPO Logistics, Align Technology and more.

Don't Write Off FANG: Cramer's 'Mad Money' Recap (Wednesday 10/31/18)

Don't Write Off FANG: Cramer's 'Mad Money' Recap (Wednesday 10/31/18)

Jim Cramer says investors need to remember how terrific these companies are, and why they can't be written off.

Cologuard® Revenue Increased 63 Percent To $118 Million, And Cologuard Test Volume Grew 49 Percent To 241,000 During Third Quarter

Cologuard® Revenue Increased 63 Percent To $118 Million, And Cologuard Test Volume Grew 49 Percent To 241,000 During Third Quarter

- Demand accelerated from healthcare providers as more than 11,000 ordered their initial Cologuard test during the third quarter, and nearly 132,000 have ordered since the test was launched

Raytheon, Northrop Grumman, Zuora: 'Mad Money' Lightning Round

Raytheon, Northrop Grumman, Zuora: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Raytheon, Northrop Grumman, Zuora, Exact Sciences.

Apple's Trillion-Dollar Market Cap: Cramer's 'Mad Money' Recap (Thur 8/2/18)

Apple's Trillion-Dollar Market Cap: Cramer's 'Mad Money' Recap (Thur 8/2/18)

This trillion-dollar level is so meaningful, Jim Cramer says, because Apple may be the first company to get here, but it won't be the last. Get ready.

Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica, A Leading Provider Of Biological Sample Preservation Technology

Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica, A Leading Provider Of Biological Sample Preservation Technology

Technology Promotes High-Quality Results from Liquid Biopsy Cancer Tests

Exact Sciences Schedules Third-quarter 2018 Earnings Call

Exact Sciences Schedules Third-quarter 2018 Earnings Call

MADISON, Wis., Oct.

EXACT Sciences Corp. Larger Than S&P 500 Component Qorvo

EXACT Sciences Corp. Larger Than S&P 500 Component Qorvo

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Qorvo Inc , according to The Online Investor.

Zoetis Could Pull Back in the Short Run, but We Have Higher Price Targets Longer

Zoetis Could Pull Back in the Short Run, but We Have Higher Price Targets Longer

ZTS discovers, develops, manufactures, and markets veterinary vaccines and medicines.

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody likes tariffs, says Jim Cramer. But Trump said he'd do it. Even so, trade and tariff fears have hit Wall Street -- and investors -- hard.

Notable Friday Option Activity: EXAS, GTLS, CARB

Notable Friday Option Activity: EXAS, GTLS, CARB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 12,345 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tripadvisor Inc , according to The Online Investor.

EXACT Sciences: Wait For a Better Buying Opportunity

EXACT Sciences: Wait For a Better Buying Opportunity

The stock still looks vulnerable to further declines from a technical perspective.

Exact Sciences: Cramer's Top Takeaways

Exact Sciences: Cramer's Top Takeaways

Kevin Conroy, chairman and CEO of Exact Sciences, tells Jim Cramer about his company's expansion plans for cancer screening tests.

TheStreet Quant Rating: C- (Hold)